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Interdisciplinary Expert Consensus Document
on Management of Type B Aortic Dissection
Rossella Fattori, MD,* Piergiorgio Cao, MD,† Paola De Rango, MD,‡ Martin Czerny, MD,§
Arturo Evangelista, MD, Christoph Nienaber, MD,¶ Hervé Rousseau, MD,# Marc Schepens, MD**
Pesaro, Rome, and Perugia, Italy; Berne, Switzerland; Barcelona, Spain; Rostock, Germany; Toulouse, France;
and Brugge, Belgium
An expert multidisciplinary panel in the treatment of type B aortic dissection reviewed available literature to
develop treatment algorithms using a consensus method. Data from 63 studies published from 2006 to
2012 were retrieved for a total of 1,548 patients treated medically, 1,706 patients who underwent open
surgery, and 3,457 patients who underwent thoracic endovascular repair (TEVAR). For acute (first 2 weeks)
type B aortic dissection, the pooled early mortality rate was 6.4% with medical treatment and increased to
10.2% with TEVAR and 17.5% with open surgery, mostly for complicated cases. Limited data for treatment
of subacute (2 to 6 weeks after onset) type B aortic dissection showed an early mortality rate of 2.8% with
TEVAR. In chronic (after 6 weeks) type B aortic dissection, 5-year survival of 60% to 80% was expected with
medical therapy because complications were likely. If interventional treatment was applied, the pooled
early mortality rate was 6.6% with TEVAR and 8.0% with open surgery. Medical treatment of uncomplicated
acute, subacute, and chronic type B aortic dissection is managed with close image monitoring. Hemody-
namic instability, organ malperfusion, increasing periaortic hematoma, and hemorrhagic pleural effusion on
imaging identify patients with complicated acute type B aortic dissection requiring urgent aortic repair.
Recurrence of symptoms, aortic aneurysmal dilation (55 mm), or a yearly increase of 4 mm after the
acute phase are predictors of adverse outcome and need for delayed aortic repair (“complicated chronic
aortic dissections”). The expert panel is aware that this consensus document provides proposal for strate-
gies based on nonrobust evidence for management of type B aortic dissection, and that literature results
were largely heterogeneous and should be interpreted cautiously. (J Am Coll Cardiol 2013;61:1661–78)
© 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.072Aortic dissection has one of the highest mortality rates of
the cardiovascular diseases, and the complexities of man-
agement remain a challenge. Since the first description of
thoracic endovascular repair (TEVAR), type B acute and
chronic dissection of the thoracic aorta has increasingly been
treated by the endovascular route (1–3). However, several
controversies continue to exist on the optimal treatment
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accepted November 8, 2012.strategy (2,3) for type B aortic dissection. To date, only 1
randomized trial of TEVAR versus medical management
for chronic type B aortic dissection has been completed
(4,5). Most published reports describing TEVAR for type B
aortic dissection consist of uncontrolled prospective or retro-
spective cohorts or case series. Furthermore, the timing of
intervention after dissection onset and complications are not
uniformly reported and defined. Patients assigned to medical
treatment, TEVAR, or open surgery often significantly differ
in baseline comorbidity illnesses and severity of the disease,
making direct comparisons among treatment strategies
difficult.
The objective of this paper is to present a consensus of
cardiovascular, vascular, and interventional specialists in an
attempt to define reliable criteria for definitions and treatment
of type B aortic dissection. As part of this objective, a
comprehensive review of available literature regarding medical,
surgical, and endovascular treatment of type B aortic dissection
has been conducted. The experts’ panel is aware that this
consensus document can provide a proposal for strategies, but
that the final decision about when an intervention is justified
a
l
d
w
r
w
a
s
m
b
R
S
d
(
m
i
s
1662 Fattori et al. JACC Vol. 61, No. 16, 2013
Consensus on Type B Aortic Dissection April 23, 2013:1661–78and what type of intervention
should be used may vary among
individual cases.
Methods
Literature search. The review
of the available literature was
planned in accordance with cur-
rent guidelines for performing
comprehensive systematic re-
views (MOOSE [Meta-analysis
of Observational Studies in Epi-
demiology]) (6). The literature
search was implemented to identify studies through a
comprehensive search of computerized databases including
PubMed, Ovid Medline, and the Cochrane Library. The
search was inclusive to June 2012 and limited to the past 6
years. Search strings included “type B aortic dissection”
combined with the terms “medical treatment,” “endovascu-
lar treatment,” and “surgical treatment.” Subheadings for
the search were the terms “acute,” “chronic,” and “subacute.”
The search was limited to studies on humans and adults only,
with at least an abstract available in English. After potentially
relevant studies were identified, additional tangential searches
were conducted using related study links within PubMed or
within a reference list of published papers.
For the analysis, studies evaluating medical, open surgi-
cal, and/or TEVAR management were eligible if they
included at least 20 patients with type B aortic dissection for
each timing (acute, subacute, chronic) and treatment cate-
gory, and reported at least 1 clinically relevant outcome or
provided data on morphological predictors of outcomes.
Type A dissection and combined hybrid endovascular and
open thoracic aorta repairs were excluded.
In evaluating multiple publications of overlapping patient
populations, studies were evaluated by the center(s) and
patient enrollment dates, and the most recent and/or most
complete series was selected to extract as many relevant
outcomes as possible. To define the timing of type B aortic
dissection, acute presentation had to be within 14 days of
onset of symptoms and chronic presentation beyond 6
weeks. An interval between 2 and 6 weeks from onset of
pain was used as the most appropriate time to define a
subacute type B aortic dissection (3). The major endpoint
was early (in-hospital and 30 days) mortality. Secondary
endpoints included early (in-hospital/30 days) stroke and
spinal cord ischemia, and long-term survival and aortic
event-free survival. For “aortic event free,” definitions pro-
vided by study investigators were generally used and detailed
as provided. An ancillary analysis was conducted to inves-
tigate morphological outcome predictors.
Expert panel. An expert panel in the treatment of type B
ortic dissection was organized by convening 7 thought
eaders from the multidisciplinary fields of cardiology, car-
Abbreviations
and Acronyms
CI  confidence interval
CT  computed
tomography
MDCT  multidetector
computed tomography
MRI  magnetic resonance
imaging
OR  odds ratio
TEVAR  thoracic
endovascular repairiothoracic surgery, vascular surgery, and interventional Tradiology. All panel members represented the Western
European geographical area and were from centers recog-
nized for aortic dissection referral. The members of the
panel convened and participated in workshops to review the
best available literature and to provide a consensus docu-
ment with suggestions for those treatments that were shown
to have sufficient evidence of clinical benefit for treatment of
type B aortic dissection. Efforts were also made to standard-
ize definitions (e.g., complicated type B aortic dissection).
Consensus method. The panel highlighted current topics
of debate regarding treatment of type B aortic dissection,
discussed specific results from the literature, and identified
evidence gaps. Treatment algorithm was drafted only when
general agreement among panelists was reached and was
based on the best-published evidence. In case of initial
disagreement, re-review of literature information and fur-
ther discussion were performed before unanimous approval.
Statistical analysis. Literature data were stratified by the
timing of dissection (acute [first 2 weeks] and chronic;
subacute [2 to 6 weeks] when available) (3,4) and type of
treatment (medical, TEVAR, open surgery). Meta-analysis
was conducted using specific statistical packages: Compre-
hensive meta-analysis package; Biostat (Borenstein M,
Hedges L, Higgins J, Rothstein H. Comprehensive Meta-
analysis Version 2, Biostat, Englewood, New Jersey, 2005);
and Review Manager (RevMan) Version 5.1 (The Nordic
Cochrane Centre, Copenhagen, Denmark). Event rates,
ranges, and corresponding 95% confidence intervals (CIs)
were used to summarize outcome data pooled from all
eligible identified studies. Comparisons of outcomes
among different treatments (medical vs. TEVAR vs. open
surgery) were combined only when treatments were applied
in the same population (same study) to make outcomes
comparable. Results from pooled comparisons were ex-
pressed as pooled odds ratios (OR) with 95% CI for
dichotomous variables.
Statistical heterogeneity was measured using the Q statistic
(p  0.10 was considered indicative of statistically significant
heterogeneity) and I2 test. A fixed-effects model was used
hen no heterogeneity existed among studies. Otherwise, the
andom effects model was used. Long-term data were reported
ith Kaplan-Meier rates as by study investigators. No pooled
nalyses of long-term results were performed because of incon-
istency in follow-up lengths. Results from ancillary analysis on
orphology predictors were similarly systematically analyzed
ut not pooled in a meta-analytical model.
esults
earch results. The assessment of studies for inclusion and
ata extraction was conducted by 1 independent reviewer
P.D.R.), and validated by the panelists during the first
eeting. The literature search identified 126 potentially of
nterest publications from 2006 to 2012. Main data from the
tudies finally included in this review are provided in
ables 1 to 4 (4,5–78). Twenty-four publications included
Result Summary for Medical Treatment in Type B Aortic DissectionTable 1 Result Summary for Medical Treatment in Type B Aortic Dissection
Author and Year (Ref. #) n Pathology
Early Mortality
n (%)
Early CVA
n (%)
Early SCI
n (%)
Mean Follow-Up
(months)
Survival Rate
(%)
Aortic Event Freedom Rate
(%)
Case series
Winnerkvist 2006 (7) 66 66 acute (14 chronic
excluded)
0 2 (3) 3 (4.5) 79 (22–179) 1 yr (100.0)
5 yrs (82.0)
10 yrs (69.0)
Any dissection death, new dissection,
aneurysm free:
5 yrs: (75.0)
10 yrs: (67.0)
Dissection death free:
5 yrs (85.0)
10 yrs (82.0)
Hata 2007
Niino 2009 (8,9)
210 Acute not complicated
(5 complicated
excluded)
6 (2.8) NA 1 (0.5) on 180 patients
50.5 37.8
on 180 patients
1 yr (97.0)
5 yrs (89.4)
10 yrs (71.8)
on 180 patients
Reintervention free:
1 yr (93.0)
5 yrs (83.9)
10 yrs (76.0)
Estrera 2006, 2007
(10,11)
159 85 acute not complicated
74 acute complicated
including 136 medical
and 23 early repair
10/136 (7.3) NA
8 (5.0)/159 overall
NA
13 (8.2)/159 overall
20 (0–67) Overall
1 yr (83.0)
5 yrs (75.0)
NA
11 reinterventions at 6 months
Kitada 2008 (12) 74 Acute 0 NA NA 12 1 yr (97.0) 1 yr (82.0)
Sakakura 2009 (13) 215 Acute 8 (3.7) NA 1 (0.5) NA NA
Chemelli-Steingruber
2009, 2010 (14,15)
50 Acute 3 (6.0) 1 (2.0) NA 36 (0–122) 1 yr (88.5)
5 yrs (70.2)
on 35 patients
Dissection death free:
1 yr (88.0)
5 yrs (74.9)
Rupture free survival:
1 yr (93.4)
5 yrs (88.5)
Dick 2010 (16) 72 Acute 4 (5.6) NA NA 36 19 NA NA
Garbade 2010 (17) 84 63 acute not complicated
21 acute complicated
7 (8.3) 12 (14.3) 1,107 days 1 yr (86.2)
3 yrs (80.9)
5 yrs (72.1)
NA
Reintervention: 22
Miyahara 2011 (18) 160 Acute 0 NA NA 33.5 (2–88) 1 yr (98.7)
3 yrs (92.2)
5 yrs (87.2)
Rupture, reintervention free:
1 yr (92.2)
3 yrs (84.2)
5 yrs (71.0)
Registries
Fattori IRAD 2006, 2008,
2010 (19–22)
390 Acute 34 (8.7) NA NA NA on 189 patients
1 yr (90.3)
3 yrs (77.6)
NA
Cumulative 1,480 6.4% 4.2% 5.3%
Neurologic complications 10.1%
Chronic dissection
Nienaber INSTEAD 2009,
2010 (4,5)
68 Subacute/chronic not
complicated
0 0 NA 2 yrs 1 yr (97.0) Aorta-related death, reintervention,
expansion free:
1 yr (82.5)
Aorta related death free:
1 yr (97.0)
CVA  cerebrovascular accident; INSTEAD  Investigation of Stent Grafts in Aortic Dissection; IRAD  International Registry of Acute Aortic Dissection; SCI  spinal cord ischemia.
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Result Summary for TEVAR in Acute Type B Aortic Dissection*Table 2 Result Summary for TEVAR in Acute Type B Aortic Dissection*
Author and Year
(Ref. #) n Pathology
Early Mortality
n (%)
Early CVA
n (%)
Early SCI
n (%)
Mean Follow-up
(months)
Survival Rate
(%)
Aortic Event Freedom Rate
(%)
Case series
Böckler 2006, 2009
(28,29)
23 Acute complicated 6 (26.0) 0 0 24 (0–56) 1 yr (62.0)
5 yrs (62.0)
Aortic event free:
1 yr (64.0)
5 yrs (45.0)
Reintervention free:
1 yr (82.0)
5 yrs (73.0)
Chen 2006 (30) 23 Acute complicated 1 (4.3) 1 (4.3) 0 27.5 14.2 NA NA
Di Tommaso 2006 (31) 26 Acute complicated 0 NA 0 29 14 (8–58) NA
3 deaths
NA
2 aortic deaths
2 late ruptures
2 redo TEVARs
Yang 2006 (32) 36 Acute complicated 1 (2.8) 0 0 15 (2–48)
Jing 2008 (33) 32 Acute complicated 1 (3.1) 0 0 18 16 (1–65) 4 yrs (86.4) 4 yrs (73.9)
Rodriguez 2008 (34) 59 Acute complicated 1 (1.7) 3 (5.1) 3 (5.1) 15.6 NA NA
Sayer 2008 (35) 38 Acute complicated 1 (2.6) 2 (5.3) 0 30 (93 at 30
months)
Reintervention free:
(55 at 30 months)
Alves 2009 (36) 45 Acute complicated 3 (6.7) NA NA 35.9 28.5 NA NA
(78 at 35.9
months)
Reinterventions free:
(79 at 35.9 months)
Chemelli-Steingruber
2009, 2010 (14,15)
38 Acute complicated 5 (13.2) 1 (2.6) 0 33 (0–97) 1 yr (81.5)
5 yrs (69.0)
on 29 patients
Dissection death survival:
1–5 yrs (82.6)
Rupture free survival:
1–5 yrs (93.1)
Conrad 2009 (37) 33 Acute complicated 4 (12) 4 (12) 2 (6) 1 yr NA NA
8 deaths at 1 yr
Feezor 2009 (38) 33 Acute complicated 7 (21.2) 4 (12.1) 5 (15.1) 5 NA NA
Guanqi 2009 (39) 72 Acute complicated 1 (1.4) 3 (4.2) 0 14.4 11 acute 1 yr (98.6) FL thrombosis
3 yrs (75.0) 1 yr (51.4)
2 yrs (53.8)
Khoynezhad 2009
Kim, 2011 (40,41)
41 Acute complicated 4 (9.8) 5 (12.2)
2 major (4.9)
3 minor (7.3)
0 on 28 patients
36 27 (1–88)
on 28 patients
1 yr (82.0)
5 yrs (78.0)
NA
on 28 patients
5 endoleaks
2 reinterventions
Manning 2009 (42) 45 Acute complicated 5 (11.1) 2 (4.4) 4 (8.9) 30  9 for IIIa NA NA
29  18 for IIIb
Sze 2009 (43) 23 Acute complicated 4 (17.4) 2 (8.7) 1 (4.3) 22.3 (0–92) NA NA
11 endoleaks
Botsios 2010 (44) 32 Acute complicated 3 (9.3) NA 1 (3.1) 32.1 18.7 (2–60)
Ehrlich 2010 (45) 32 Acute complicated 4 (12.5) NA 3 (9.4) 26 23 1 yr (81.0) 1 yr (78.0)
5 yrs (76.0) 5 yrs (61.0)
Continued on the next page
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ContinuedTable 2 Continued
Author and Year
(Ref. #) n Pathology
Early Mortality
n (%)
Early CVA
n (%)
Early SCI
n (%)
Mean Follow-up
(months)
Survival Rate
(%)
Aortic Event Freedom Rate
(%)
Garbade 2010 (17) 46 27 acute complicated 9 (19.6) 11 (23.9) 1,107 days 1 yr (80.0) NA
19 acute uncomplicated 3 yrs (73.3)
5 yrs (56.3)
Parsa 2010 (46) 22 Acute complicated 1 (4.5) 0 1 (4.5) 7.1 (1–38) NA NA
Cumulative
acute/chronic
Cumulative acute/chronic
Zeeshan 2010 (47) 45 Acute complicated 2 (4.4) 3 (6.7) 6 (13.3) 37 (2 months–7 yrs) 1 yr (82.0) NA
5 yrs (79.0) 2 deaths
3 retrodissections
7 reinterventions
Tang 2011 (48) 30 Acute complicated 1 (3.3) NA 0 12 8 (1–19) NA 1 death
O’Donnell 2011 (49) 28 27 acute complicated 2 (7.2) 3 (10.7) 1 (3.6) 21 (1–45) NA NA
1 major 85% overall 2 reinterventions
2 minor
Shu 2011 (50) 45 Acute complicated 2 (4.4) 0 0 13 (1–36) 1 yr (95.6)
3 yrs (96.6)
Steuer 2011 (51) 60 50 acute complicated 2 (3.3) 3 (5.0) 1 (1.7) 3.7 yrs 3 yrs (90.0) Reintervention freedom:
10 subacute
complicated
5 yrs (87.0) 3 yrs (68.0)
5 yrs (65.0)
Registries
Fattori IRAD 2008,
2006 (19,20)
43 Acute complicated 5 (11.6) NA 1 (2.3) 2.3 yrs median on 29 patients
1 yr (88.9)
3 yrs (76.2)
Torsello 2010
TRAVIATA (23)
32 Acute complicated 0 0 0 23.1 10.1 NA NA
VIRTUE 2011 (24) 50 Acute complicated 4 (8.0) 4 (8.0) 1 (2.0) 23.1
Zipfel 2011 (25) 25 Acute complicated 5 (20.0) NA NA NA NA NA
Ehrlich 2012 Talent
Thoracic Registry
(26)
29 Acute complicated 5 (17.2) 2 (6.9) 0 53 41 1 yr (79.0)
5 yrs (61.0)
Treatment failure (rupture,
device-related
complications, aortic
death, sudden death,
reintervention)
freedom:
1 yr (82.0)
5 yrs (77.0)
Administrative†
Brunt 2011 NIH (27) 991 Acute emergent 107 (10.8) 37 (3.7) 32 (3.2) NA NA NA
Brunt 2011 NIH (27) 282 Acute elective 9 (3.2) 10 (3.5) 0 NA NA NA
Cumulative 2,359 10.2% 4.9% 4.2%
*Data on endovascular treatment of type B dissection included use of a number of different types of stent grafts. †In-hospital data.
FL false lumen; NIH National Institutes of Health; TEVAR thoracic endovascular aortic repair; TRAVIATA Treatment of Thoracic Aortic Disease with the Valiant Stent Graft; VIRTUE VALIANT Thoracic Stent Graft Evaluation For the Treatment of Descending Thoracic
Aortic Dissections- Post Marketing Surveillance Registry; other abbreviations as in Table 1. 1665
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Consensus on Type B Aortic Dissection April 23, 2013:1661–78duplicative or overlapping data and were excluded (Online
Refs. 79–102). Of the remaining 102, another 19 were
excluded because of small numbers (20 cases for type of
treatment or timing of disease) (Online Refs. 103–121).
Most retrieved studies were retrospective or observational
studies without controls, and often had mixed populations.
Only 2 identified studies were randomized (4,5) (Online
Ref. 122), but published outcomes were available only for 1
study (4,5). Nine registries were identified, but data could be
included only for 5 (19–26). In the remaining studies
(Online Refs. 123–126), no detailed information was
retrievable according to the inclusion criteria for search.
Reasons for exclusions of major registries are shown in
Table 5. Data from administrative codes were retrievable
from 3 studies, but only 1 (27) could be included for
completeness in reporting (Online Refs. 127,128). Only
in-hospital data were available for this study. Overall, 15
studies were excluded because no detailed information on
outcomes could be retrieved (Online Refs. 123–126,129–137).
Finally, 2 studies were excluded because of reporting on
complex stent grafts (Online Refs. 138,139), and another 2
were excluded because of meta-analysis of included studies
Result Summary for Open Surgery in Type B Aortic Dissection*Table 3 Result Summary for Open Surgery in Type B Aortic Dis
Author and Year
(Ref. #) n Pathology
Early Mortality
n (%)
Earl
n
Case series
Estrera 2007 (11) 23 Acute complicated 4 (17.4)
Bozinovski 2008 (64) 76 Acute complicated 17 (22.4) 5
Shimokawa 2008 (65) 24 Acute complicated 2 (8.3) N
Zeeshan 2010 (47) 20 Acute complicated 8 (40)
Murashita 2012 (66) 31 Acute complicated 6 (19.4) 2
Registries
Trimarchi, IRAD 2006 (22) 82 Acute complicated 24 (29.3) 8
Administrative†
Brunt NIS† 2011 (27) 991 Acute emergent 173 (17.5) 61
Brunt NIS† 2011 (27) 282 Acute elective 16 (5.6) 5
Cumulative acute 1,529 17
Chronic dissection
Miyamoto 2008 (67) 40 Chronic complicated 0 2
Mutsuga 2010 (68) 33 Chronic complicated 0 2
Zoli 2010 (69) 104 Chronic complicated 10 (9.6) 6
Cumulative chronic 177 8
*Data on endovascular treatment of type B dissection included use of a number of different type
NIS  National Institutes of Science; other abbreviations as in Tables 1 and 2.(Online Refs. 140,141). nThe remaining studies included data on 1,548 patients
treated medically (1,480 for acute [7–22] and 68 patients
for chronic or subacute aortic dissection [4,5]); 1,706
patients treated with open surgery (1,529 for acute
[11,22,27,47,64 – 66] and 177 for chronic aortic dissec-
tion [67– 69]); and 3,457 patients treated with TEVAR
(2,359 for acute [14,15,17,19,20,23–51] and 1,098 for chronic
or subacute aortic dissection [4,5,24,25,29,32–36,39,52–63]).
ine additional studies were included because of report-
ng on morphology predictors of outcome in type B aortic
issection (70 –78), for a total of 63 studies finally
ncluded in the present review. Only a few studies
eported on subacute dissections (4,5), but there were no
lear distinction in reporting outcomes for dissections
ssessed at 2 to 6 weeks from onset and those assessed
ater; therefore, it was not possible to separately analyze
nd report cumulative data.
Figure 1 outlines the results of the search strategy.
ultiple references for the same study, if providing addi-
ional details, were retained. A complete list of references of
xcluded studies are shown in the Online Appendix.
The identified available literature was found to have
on*
Early SCI
n (%)
Mean Follow-Up
(months)
Survival
Rate (%)
Aortic Event Freedom
Rate (%)
NA 20 (0–67) NA NA
5 (6.6) NA NA NA
1 (4.2) 28.1 14.8 (10.3–68.1) 5 yrs (82.6) Reintervention, aortic
death free:
1 yr (95.2)
5 yrs (68.0)
2 (10.0) 37 (2 months–7 yrs) 1 yr (58.0)
3 yrs (52.0)
5 yrs (44.0)
NA
2 (6.5) 11.5 (1–77) 1 yr (74.1)
5 yrs (64.8)
Rupture, reintervention,
expansion free:
1 yr (83.0)
5 yrs (58.7)
4 (4.9) NA NA NA
25 (2.5) NA NA NA
0 NA NA NA
5.9% 3.3%
0 9.8 5.1 yrs (4–23) 5 yrs (92.0)
10 yrs (64.0)
Reintervention, dissection,
aneurysm, free:
5 yrs (85.0)
10 yrs (78.0)
3 (9.1) NA NA NA
5 (4.8) 5.7 4.5 yrs 1 yr (78.0)
5 yrs (68.0)
10 yrs (59.0)
Reintervention free:
1 yr (99.0)
5 yrs (93.0)
10 yrs (83.0)
5.7% 5.5%
nt grafts. †In-hospital data.secti
y CVA
(%)
NA
(6.6)
A (0)
0
(6.5)
(9.8)
(6.2)
(1.8)
.5%
(5)
(6.1)
(5.8)
.0%umerous limitations, including high heterogeneity in
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n
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indications, and timing for treatment and outcome data.
Literature Results and Panelists Suggestions
Acute type B aortic dissection. DEFINITION OF
OMPLICATIONS IN ACUTE TYPE B AORTIC DISSECTION.
There were no uniform criteria to define “complicated”
acute type B aortic dissection usually justifying a more
aggressive treatment approach. According to the pub-
lished literature, approximately 25% of patients present-
ing with acute type B aortic dissection are complicated at
admission by malperfusion syndrome or hemodynamic
instability, resulting in a high risk of early death if
untreated (19 –21).
Severe hypertension, a typical finding associated with
dissection onset, usually recedes with expectant manage-
ment. Refractory hypertension (hypertension persisting
despite 3 different classes of antihypertensive therapy at
aximal recommended or maximal tolerated doses), if
ot present in the clinical history before the onset of
issection, is considered a sign of instability or of renal
alperfusion (3) (Online Ref. 142). International Regis-
try of Acute Aortic Dissection (IRAD) trial data showed
that in-hospital mortality after medical management was
significantly increased in average-risk patients with type
B aortic dissection under medical therapy with refractory
hypertension/pain compared with those without these
features (35.6% vs. 1.5%; p  0.0003) (21).
Malperfusion syndrome is reported in about 10% of
patients with type B aortic dissection due to decreased
perfusion of aortic branches (spinal, iliac, or visceral
arteries) that typically leads to paraparesis or paraplegia,
lower limb ischemia, abdominal pain, nausea, and diar-
rhea. However, clinical signs of organ malperfusion may
be too subtle to be detected early. Mesenteric and celiac
artery malperfusion may be associated with an increase in
laboratory markers (bilirubin, amylases, hepatic, and
intestinal enzymes). Multidetector computed tomogra-
phy (MDCT) or magnetic resonance imaging (MRI)
findings, such as true lumen compression, or an intimal
flap inside the renal, celiac, or mesenteric arteries, carry a
high suspicion of visceral malperfusion. Delay or absence
of nephrographic effect during the late phase of contrast-
enhanced CT scan, often accompanied by an increase in
serum creatinine and/or refractory hypertension, indi-
cates renal malperfusion (19 –21).
An increase in perioaortic hematoma and hemorrhagic
pleural effusion in 2 subsequent CT examinations have
been shown as findings of impending rupture and might
have particular relevance if associated with symptoms
(19 –21).
Patients with severe hypotension (90 mm Hg systolic)
or shock at presentation should be considered at high risk of
death (19–21).PANELISTS’ SUGGESTIONS FOR DEFINITION OF COMPLICATED
TYPE B ACUTE AORTIC DISSECTION.
• Malperfusion is indicative of impending organ failure
and must be recognized early. Diagnosis of static or
dynamic organ malperfusion is corroborated by labo-
ratory markers (bilirubin, amylases, enzymes, creati-
nine) and imaging data.
• Hypertension is indicative of complications in acute
type B aortic dissection only when associated with
malperfusion or persisting with uncontrolled high
values despite full medical therapy.
• Increases in perioaortic hematoma and hemorrhagic
pleural effusion in 2 subsequent CT examinations during
medical expectant management of acute type B aortic
dissection are findings suggestive of impending rupture.
ACUTE TYPE B AORTIC DISSECTION. OUTCOME DATA FROM
MEDICAL THERAPY. There are no completed randomized
data on comparison of TEVAR versus open surgery or
versus medical therapy published results in acute type B
aortic dissection (Online Ref. 122), and unfortunately many
studies do not make a clear distinction between patients
presenting with complicated and uncomplicated patterns.
Outcome data of medical therapy were available for 1,480
patients who underwent conservative medical management
for acute type B aortic dissection, as indicated in Table 1
(7–22). In the majority of cases, patients who underwent
medical therapy presented with uncomplicated dissection,
although a percentage required early interventions for com-
plications that developed during hospital stay. A minority of
patients with complications was treated with medical ther-
apy only, either due to the lack of appropriate facilities or
due to the presence of comorbidities or morphology that
made open surgery or TEVAR not feasible. Complications
of medical therapy were reported by investigators as “devel-
oping” or “occurring” in dissections under medical manage-
ment, thereby excluding those that occurred on admission
or after a different strategy of treatment (TEVAR, open
surgery) was applied after initial medical expectant policy.
However, this was not always specified by investigators
and might represent a source of bias. For acute aortic
dissections treated medically, the pooled early mortality
rate was 6.4% (95% CI: 5.1% to 7.9%). The pooled rates
of stroke and spinal cord ischemia developing early
during medical management alone were 4.2% (95% CI:
2.3% to 7.4%) and 5.3% (95% CI: 3.4% to 8.4%),
respectively, with a combined early neurological compli-
cation event rate of 10.1% (95% CI: 7.5% to 13.5%).
Long-term survival ranged from approximately 70.2% to
89% at 5 years (7–12,14,15,17–22). Aortic adverse event
freedom (including aortic death, rupture, new dissection,
enlargement, reintervention) ranged from 75% to 88.5%
at 5 years, but there were variable event definitions
among studies (Table 1).
Result Summary for TEVAR in Chronic Type B Aortic Dissection*Table 4 Result Summary for TEVAR in Chronic Type B Aortic Dissection*
Author and Year
(Ref. #) n Pathology
Early Mortality
n (%)
Early CVA
n (%)
Early SCI
N (%)
Mean Follow-Up
(months)
Survival Rate
(%)
Aortic Event Freedom Rate
(%)
Case series
Thompson 2007 (52) 52 Chronic complicated
(including 2 valiant
potential overlapping
with Mani 2012)
1 (1.9) 2 (3.8) 0 5 NA NA
Suzuki 2006 (53) 45* *43 chronic complicated
2 acute
0 1/45 (2.2) 0 62 (18–101) NA
5 late deaths
NA
Yang 2006 (32) 40 Chronic complicated 0 0 0 15 (2–48) NA NA
Yuan 2007 (54) 27 Chronic 0 0 0 48 (7–87) NA NA
Flecher 2008 (55) 28 Chronic complicated 4 0 0 20.8 (1–80) NA NA
Jing 2008 (33) 35 Chronic complicated 0 0 0 17 14 (1–65) NA
1 late death
NA
Rodriguez 2008 (34) 47 Chronic complicated 7 2 1 15.6 NA NA
Sayer 2008 (35) 40 Chronic complicated 3 (7.5) chronic 0 0 30 (66.5) at
30 months
Reintervention free:
(62) at 30 months
Alves 2009 (36) 61 Chronic complicated 2 (3.3) chronic NA NA 35.9 28.5 NA NA
(93) at
35.9 months
Reintervention free:
(78) at 35.9 months
Böckler 2009 (29) 31 Chronic complicated 0 0 0 32.1 25 (1–95) NA NA
Chaikof 2009 (56) 33 Chronic complicated NA 1 (3.0)
chronic
0 11 (73) at 1 yr NA
Kim 2009 (57) 72 Chronic 0 0 0 64.4 38.8 (5–97) NA Dissection mortality free:
5 yrs (98.3)
5 deaths
1 aorta
related
Guanqi 2009 (39) 49 Chronic complicated 4 (8.2) chronic 1 (2.0)
chronic
0 22.1 20.8
chronic
NA NA
Ohtake 2010 (58) 23 Chronic 0 NA NA 37 (4–80) NA NA
Xu 2010 (59) 84 Chronic 1 (1.2) 0 0 33.2 (6–86) 5 yrs (84.4) 5 yrs (75.2)
Parsa 2011 (60) 51 Chronic complicated 0 0 0 27 16 (2–60) 5 yrs (77.7) Aortic survival:
5 yrs (98)
Reintervention free:
5 yrs (77.3)
Kang 2011 (61) 76 Chronic complicated 4 (5) 1 0 34 1 yr (86) Death, reintervention free:
1 yr (72)
3 yrs (80) 3 yrs (59)
Reintervention free:
1 yr (83)
3 yrs (73)
Andacheh 2012 (62) 73 Chronic complicated 10 (14) 1 1 18 1 yr (81) Aortic death survival:
1 yr (86)
Continued on the next page
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April 23, 2013:1661–78 Consensus on Type B Aortic DissectionACUTE TYPE B AORTIC DISSECTION. OUTCOME DATA
FROM TEVAR. Thirty studies were identified with out-
ome data of TEVAR for acute type B aortic dissection
14,15,17,19,20,23–51). Nineteen included only acute dis-
ections, whereas 11 reported acute and chronic dissection
ases in separate groups. In most of the papers, indication
or TEVAR was complicated acute type B dissection;
owever, this finding was not always specified (27), and
riteria for defining complicated were variable. As a conse-
uence, the exact number of complicated versus uncompli-
ated cases could not be accurately determined. Analysis of
ata was performed with the understanding that this dis-
repancy might create some bias. A summary of pertinent
esults for TEVAR of acute type B aortic dissection is
hown in Table 2, reporting available data from 2,359
atients. The early pooled mortality rate was 10.2% (95%
I: 9.0% to 11.6%). Pooled rates of early stroke and spinal
ord ischemia after treatment were 4.9% (95% CI: 4.0% to
.0%) and 4.2.% (95% CI: 3.3% to 5.2%), respectively.
urvival rates ranged from 56.3% to 87% at 5 years. Freedom
rom aortic events (as a variable reported in Table 2) ranged from
5% to 77% at 5 years.
ACUTE TYPE B AORTIC DISSECTION. OUTCOME DATA FROM
OPEN SURGERY. Outcome data on 1,529 patients with acute
complicated type B aortic dissection submitted to open
surgical repair were analyzed for this consensus document
(Table 3) (11,22,27,47,64–66). The pooled early mortality
rate was 17.5% (95% CI: 15.6% to 19.6%). The pooled
mean rates of early stroke and spinal cord ischemia after
treatment were 5.9% (95% CI: 4.8% to 7.3%) and 3.3%
(95% CI: 2.4% to 4.5%), respectively. Five-year survival
rates ranged from 44% to 64.8%. Freedom from aortic
events and reintervention ranged from 58.7% to 68% at 5
years (Table 3).
COMPARISON OF MEDICAL THERAPY VERSUS TEVAR AND
OPEN SURGERY VERSUS TEVAR FOR ACUTE TYPE B AORTIC
DISSECTION. In the published literature, direct comparison
etween TEVAR, open surgery, and medical therapy was
ikely invalidated by unbalanced populations (unmatched
llness conditions and rates of complicated vs. uncompli-
ated cases of patients assigned to each treatment). This
ight produce a too optimistic interpretation of the
esults, with an overestimation of low mortality and
omplication rates in populations at lower risks (uncom-
licated cases) usually assigned to medical therapy with
espect to worse populations (more often complicated)
reated by TEVAR and open surgery. One unpublished
andomized controlled trial, which compared medical
herapy versus TEVAR in clearly uncomplicated acute
ype B dissections, recently released data that showed no
arly mortality among 31 patients randomized to best
edical treatment and 30 patients assigned to TEVAR, buthad 10% treatment crossovers that occurred a few days afterCo T R *D
a A
Excluded Registries in Type B Aortic DissectionTable 5 Excluded Registries in Type B Aortic Dissection
Author and Year (Ref. #) n Pathology
Early Mortality
n (%)
Early CVA
n (%)
Early SCI
n (%)
Mean Follow-Up
(months) Reasons for Exclusions
Excluded registries*
Buth EUROSTAR† 2007
(123)
215 TEVAR 102 acute 113 chronic,
including undefined
number with aortic
arch involvement
(Type A?)
NA 7 (3.3)
4 acute
3 chronic
3 (1.4)
3 acute
0 chronic
NA Including 78 involvement of aortic
arch or ascending aorta,
606 total TEVAR repairs
(291 aneurysms, 215
dissections, 67 ruptures,
24 false aneurysms and
9 infections)
Day New Zealand 2009
(124)
39 TEVAR NA 7 (18.0) NA NA NA No details on type and timing of
dissection
Eggebrecht ERAR European
Registry on
Endovascular Aortic
Repair Complications
2009 (125)
26 retrodissection NA NA NA NA NA Focused on repairs for retrograde
dissection after TEVAR
Jakob E-vita Registry hybrid
2011 (126)
88 TEVAR 88 acute 16 (18.0) NA NA NA Specific designed complex
endograft for hybrid repairs
Excluded administrative studies*
Sachs 2010 NIH† (127) 1,381 TEVAR
3,619 open
NA 146 (10.6) in TEVAR
688 (19.0) in open
NA NA NA No details on type of dissection
Conrad Medicare† 2010
(128)
833 TEVAR
1,868 Open
NA 76 (9.0) in TEVAR
399 (21.0) in open survival:
5 yrs (58.2) in TEVAR
5 yrs (50.6) in open
NA NA NA No details on type and timing of
dissection
*See the Online Appendix for the excluded references. †In-hospital data.
EUROSTAR  European Cobalt Stent with Antiproliferative for Restenosis Trial; other abbreviations as in Tables 1 and 2.
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year data supported higher efficacy of TEVAR in allowing
true lumen expansion and false lumen decrease (Brunkwall
ESVS, personal communication, 2012).
Direct comparison of outcomes between medical therapy
and TEVAR for acute aortic dissection was available from 3
published studies (Fig. 2, Table 6); 1 was a registry
(15,17,19). According to meta-analysis of these studies, the
early mortality rate was lower with medical therapy alone
(Fig. 2A) (odds ratio [OR]: 0.50; 95% CI: 0.27 to 0.95),
whereas the risk of early neurologic complications (stroke
and spinal cord ischemia) was comparable (Fig. 2B) (OR:
0.55; 95% CI: 0.23 to 1.32). Three studies (19,27,47) were
available for direct comparisons of outcomes between
TEVAR and open surgery for acute type B aortic
dissection (Fig. 3, Table 6); 1 was a registry (19,20), and
another was based on administrative codes that did not
specify whether dissections were complicated or not (47).
Pooled early mortality rate was significantly higher after
open surgery (OR: 2.66; 95% CI: 1.37 to 5.17) (Fig. 3A).
There were no significant differences in rates of early
stroke (OR: 0.90; 95% CI: 0.30 to 0.95) or spinal cord
ischemia (OR: 0.82; 95% CI: 0.50 to 1.33) after repair
Figure 1 Results from Literature Search
TEVAR  thoracic endovascular repair.(Figs. 3B and 3C).PANELISTS’ SUGGESTIONS FOR TREATMENT OF ACUTE TYPE B
AORTIC DISSECTION.
• Patients with uncomplicated acute type B aortic dis-
section should be treated with medical therapy. At
present, there is no evidence of advantage with TE-
VAR or open surgery.
• TEVAR, when feasible, should be considered the
first-line treatment in complicated acute type B dis-
section. A survival benefit is achieved by TEVAR in
comparison with open surgery. A recommended treat-
ment algorithm is shown in Figure 4.
• Aneurysmal evolution and eventual rupture may occur
even in the absence of warning symptoms, and imag-
ing follow-up must be performed at regular intervals.
MDCT or MRI scan should be used to monitor
uncomplicated dissections and should be performed
at admission, 7 days, discharge, and 6 weeks (3),
because the risk of instability is higher in the early
phase (Fig. 4).
• Despite reasonably low early operative morbidity and
mortality, there is the likelihood of aortic adverse
events after TEVAR, and all patients need to be
followed with imaging after treatment.
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Consensus on Type B Aortic Dissection April 23, 2013:1661–78Subacute type B aortic dissection. SUBACUTE TYPE B AORTIC
DISSECTION. OUTCOME DATA. Very limited outcome data
re available for patients with subacute aortic dissection, either
omplicated or uncomplicated. The largest series of patients,
ith subacute and chronic (between 2 and 54 weeks from
nset) uncomplicated type B aortic dissection came from the
NSTEAD (Investigation of Stent Grafts in Aortic Dissec-
ion) trial (4,5). This prospective randomized trial included 72
atients managed with TEVAR and reported a primary
uccess rate of 95.7%, an early mortality of 2.8%, a stroke rate
f 1.4%, and a 2.9% rate of spinal ischemia. Eighteen percent
f patients required secondary procedures.
The data from the VIRTUE (VALIANT Thoracic Stent
raft Evaluation For the Treatment of Descending Thoracic
ortic Dissections- Post Marketing Surveillance Registry)
egistry (24), including 24 patients with complicated subacute
ype B aortic dissections treated with TEVAR, showed a 100%
rimary procedural success rate, an early mortality rate of 1.8%,
nd no late deaths. No strokes or cases of spinal cord ischemia
ere recorded. Change in aortic morphology (expanding di-
meter 4 mm, new onset of periaortic hematoma, and/or
leural hemorrhagic effusion), refractory hypertension (accord-
ng to previous definition), recurrent thoracic pain, and malp-
rfusion were found to be associated with negative prognosis in
he subacute phase (4,5).
PANELISTS’ SUGGESTIONS FOR MANAGEMENT OF TYPE B
SUBACUTE AORTIC DISSECTION.
• The subacute phase in aortic dissection (2 to 6 weeks
from onset) may sometimes reveal signs of instability,
Figure 2 Comparison of Early (30 Days/In-Hospital) Outcomes
(A) Mortality: TEVAR versus medical therapy. (B) Neurological complications: TEVA
International Registry of Acute Aortic Dissection; other abbreviation as in Figure 1.such as changes in aortic morphology (expanding diam- feter 4 mm, new onset of periaortic hematoma, and/or
pleural hemorrhagic effusion), refractory hypertension,
recurrent thoracic pain, and recurrent malperfusion. In
these cases, TEVAR may be considered. However, data
to support prognosis and complication rates in subacute
type B aortic dissection are very limited. An algorithm for
treatment of subacute type B aortic dissection suggested
by this consensus document is shown in Figure 5.
hronic type B aortic dissection. DEFINITION OF
OMPLICATIONS IN CHRONIC TYPE B AORTIC
ISSECTION. Long-term prognosis of chronic type B dis-
ection is sobering, with just 60% to 80% survival estimates
t 5 years using conservative management because compli-
ations and aneurysm expansion are likely. Once the aortic
iameter exceeds 55 to 60 mm, the risk of rupture is
stimated at 30% per annum (3). Even if medical therapy is
onsidered the best option for uncomplicated type B aortic
issection, the effect of medical therapy may delay the
xpansion of the descending aorta, but would hardly
nhance the remodeling process. Late interventions are
ften performed in chronic type B aortic dissection for
evelopment of complications, such as for aneurysm
xpansion, progressive/new dissection, and other related
dverse events from the unresolved dissection process.
ecurrence of symptoms, aneurysmal dilation (55 mm),
r an aortic yearly increase of 4 mm are all indicative of
chronic complicated aortic dissections” because of
igher risk without treatment. A maximum aortic diam-
ter 40 mm at admission and the presence of a patent
Medical Therapy and TEVAR in Acute Type B Aortic Dissections
us medical therapy. CI  confidence interval; df  degrees of freedom; IRAD With
R versalse lumen have the most clinical data to evaluate
1673JACC Vol. 61, No. 16, 2013 Fattori et al.
April 23, 2013:1661–78 Consensus on Type B Aortic Dissectionpredictability of the development of dissection-related
events (70 –78). Patients without these findings were
reported to have the highest freedom from aortic enlarge-
ment rates, ranging from 97% to 100% at 1 year and from
84% to 89.2% at 10 years (70 –78). For patients with only
partially thrombosed false lumen, the 1- and 3-year freedom
from mortality ranged from 68.4% to 84.6% (73). Based on
these observations, many investigators recommended more
frequent follow-up and possible early intervention in pa-
tients with these adverse predictors. Additional predictors of
outcome are shown in the Online Table.
PANELISTS’ SUGGESTIONS FOR DEFINITION OF COMPLICATIONS
IN CHRONIC TYPE B AORTIC DISSECTION.
• In patients under medical management after the acute
phase, recurrence of symptoms, aneurysmal dilation
(55 mm), or a aortic yearly increase of 4 mm are
Direct Comparison of TEVAR Versus Medical Therapy and TEVAR VTable 6 Direct Comparison of TEVAR Versus Medical Therapy a
Author and Year (Ref. #) n Pathology
Early M
n (
TEVAR vs. medical
Chemelli-Steingruber TEVAR
2010 (15)
38 Acute complicated 5 (
Chemelli-Steingruber medical
2010 (15)
50 Acute 3 (
Garbade TEVAR 2010 (17) 46 27 acute complicated
19 acute uncomplicated
9 (
Garbade medical 2010 (17) 84 63 acute uncomplicated
21 acute complicated
7 (
Fattori IRAD TEVAR 2008
(19,20)
43 Acute complicated 5 (
Fattori IRAD medical 2008
(19)
390 Acute 34 (
TEVAR vs. open
Zeeshan Open 2010 (47) 20 Acute complicated 8 (
Zeeshan TEVAR 2010 (47) 45 Acute complicated 2 (
Fattori Open 2008 (19) 59 Acute complicated 20 (
Fattori TEVAR 2008, 2006
(19, 20)
43 Acute complicated 5 (
Brunt NIS* Open 2011 (27) 991 Acute emergent 173 (
Brunt NIS* TEVAR 2011 (27) 991 Acute emergent 107 (
Brunt NIS* Open 2011 (27) 282 Acute elective 16 (
Brunt NIS* TEVAR 2011 (27) 282 Acute elective 9 (
*In-hospital data.
Abbreviations as in Tables 1 to 3.indicative of higher worse prognosis without addi-tional treatment (chronic complicated type B aortic
dissections). An algorithm for treatment of chronic
type B aortic dissections is shown in Figure 6.
CHRONIC TYPE B AORTIC DISSECTION. OUTCOME DATA
FROM TEVAR. In the present literature search, 22 studies with
data regarding TEVAR of chronic type B aortic dissection
were identified; 11 included both acute and chronic cases in
separated groups (4,5,24,25,29,32–36,39,52–63). Most publi-
cations identified indications for treatment of complicated
chronic dissection; however, 2 included uncomplicated cases
(4,5,25), and 4 (54,57,58,59) did not provide further informa-
tion on the coexisting complications. Furthermore, most stud-
ies did not specify whether treatment was performed during
the subacute phase; therefore, analysis was performed on all
available patient data with the understanding that pooling of
subacute and true chronic dissections and complicated and
Open Surgery in Acute Type B Aortic DissectionEVAR Versus Open Surgery in Acute Type B Aortic Dissection
y Early CVA
n (%)
Early SCI
n (%)
Mean Follow-Up
(months)
Survival Rate
(%)
1 (2.6) 0 33 (0–97) Dissection-death survival:
1–5 yrs (82.6)
Rupture free survival:
1–5 yrs (93.1)
1 (2.0) NA 36 (0–122) Dissection death free:
1 yr (88.0)
5 yrs (74.9)
Rupture free survival:
1 yr (93.4)
5 yr (88.5)
11 (23.9) 1,107 days 1 yr (80)
3 yrs (73.3)
5 yrs (56.3)
12 (14.3) 1,107 days 1 yr (86.2)
3 yrs (80.9)
5 yrs (72.1)
NA 1 (2.3) 2.3 yrs median on 27 patients
1 yr (88.9)
3 yrs (76.2)
NA NA 2.3 yrs median on 189 patients
1 yr (90.3)
3 yrs (77.6)
0 2 (10.0) 37 (2 months–
7 yrs)
1 yr (58.0)
3 yrs (52.0)
5 yrs (44.0)
3 (6.7) 6 (13.3) 37 (2 months–
7 yrs)
1 yr (82.0)
5 yrs (79.0)
4 (6.8) 3 (5.1) NA NA
NA 1 (2.3) 2.3 yrs median Over 29 patients:
1 yr (88.9)
3 yrs (76.2)
61 (6.2) 25 (2.5) NA NA
37 (3.7) 32 (3.2)
5 (1.8) 0 NA NA
10 (3.5) 0ersusnd T
ortalit
%)
13.2)
6.0)
19.6)
8.3)
11.6)
8.7)
40.0)
4.4)
33.9)
11.6)
17.5)
10.8)
5.7)
3.2)uncomplicated patients might create some bias. A summary of
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Consensus on Type B Aortic Dissection April 23, 2013:1661–78pertinent morbidity and mortality information for TEVAR of
1,098 patients with chronic type B aortic dissection is shown in
Table 4. The pooled early mortality rate for TEVAR of
chronic aortic dissection was 6.6% (95% CI: 5.0% to 8.7%).
Pooled rates of early stroke and spinal cord ischemia were 1.9%
(95% CI: 1.1% to 3.0%) and 1.5% (95% CI: 0.0% to 2.5%),
respectively. Five-year survival rates were reported as ranging
from 77.7% to 84.4%. Freedom from reintervention was
around 83% at 1 year and 72% at 3 years (Table 4).
CHRONIC TYPE B AORTIC DISSECTION. OUTCOME DATA
FROM OPEN SURGERY. Only 3 publications including 177
atients were found in the literature with contemporary
ata on open surgical outcomes of treatment of chronic
ype B aortic dissection (67– 69). The pooled early
ortality rate was 8.0% (95% CI: 4.5% to 13.9%), and
Figure 3 Comparison of Early (30 Days/In-Hospital) Outcomes
(A) Mortality: TEVAR versus open surgery. (B) Stroke: TEVAR versus open surgery.
Figures 1 and 2.ooled rates of early stroke and spinal cord ischemia were.7% (95% CI: 3.1% to 10.2%) and 5.5% (95% CI: 2.8%
o 10.5%), respectively (Table 3). The 1- (78%) and
-year (68% to 92%) survival rates were similar to the
ates following TEVAR, whereas rates of reintervention
ere much lower in the first year (freedom 99%) accord-
ng to the few available data.
PANELISTS’ SUGGESTIONS FOR TREATMENT OF CHRONIC
TYPE B AORTIC DISSECTION.
• Most chronic type B aortic dissections are managed
medically until complications develop. A tight control
of systemic pressure with best medical treatment is of
utmost importance to limit false lumen aneurysmal
dilation over time.
• Recurrence of symptoms, aneurysmal dilation (total
Open Surgery and TEVAR in Acute Type B Aortic Dissections
pinal cord ischemia: TEVAR versus open surgery. Abbreviations as inWith
(C) Saortic diameter 55 mm), or a yearly increase (4
1675JACC Vol. 61, No. 16, 2013 Fattori et al.
April 23, 2013:1661–78 Consensus on Type B Aortic Dissectionmm) of aortic diameter should be considered signs of
instability in the chronic phase and indication for
TEVAR, or in unsuitable anatomy, indication for
open surgery (Fig. 6). Early mortality in complicated
Figure 4 Algorithm for Management of Acute Type B Aortic Dis
Abbreviation as in Figure 1.
Figure 5 Algorithm for Management of Subacute Type B Aortic
Abbreviation as in Figure 1.chronic type B aortic dissection is lower for TEVAR
compared with open surgery.
• In uncomplicated chronic type B aortic dissection, yearly
clinical and imaging follow-up is recommended, irrespec-
ion
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Consensus on Type B Aortic Dissection April 23, 2013:1661–78tive of diameter and treatment applied (TEVAR/
medical/open surgery).
iscussion
definition of different clinical patterns of type B aortic
issection and corresponding algorithms of treatment has been
ade possible for this consensus document with the analysis of
he mortality and complications rates of more than 6,700
atients reported in the available literature. This may substan-
ially help the operating physician in selecting different modal-
ties of treatment for type B aortic dissection. However,
tratification of type B aortic dissection outcome by timing
i.e., acute first 2 weeks, subacute 2 to 6 weeks, and chronic
after 6 weeks from symptoms onset]) might not be represen-
ative of the entire clinical scenario and needs to be standard-
zed. Proposed strategies suggest that medical management
ith close imaging follow-up is the best strategy for uncom-
licated type B aortic dissections with acute subacute and
hronic presentation, whereas TEVAR should be applied to
omplicated cases and suitable anatomy, to decrease the mor-
ality risk of open surgery.
Nevertheless, the strength of proposals provided by this
onsensus document is limited, especially for aortic dissec-
ions in the subacute phase, because of the large heteroge-
eity among studies and the lack of high-quality data; most
esults were from uncontrolled, nonrandomized retrospec-
ive trials or registries.
tudy limitations. This consensus document analysis should
Figure 6 Algorithm for Management of Chronic Type B Aortic D
Abbreviation as in Figure 1.e interpreted cautiously in light of shortcomings of the dvailable data. 1) The major evidence gap in reporting on type
aortic dissection was identified by panelists in the combina-
ion of complicated and uncomplicated dissections with vari-
ble criteria to define complicated cases and subjective indica-
ion for applying different types of treatments. This discrepancy
ight create some relevant selection bias, such as in the
omparison of medical therapy (most uncomplicated cases with
arger numbers) and invasive treatment with TEVAR/open
urgery. 2) Another important shortcoming is the absence of a
onsistent number of randomized trials comparing TEVAR
ith open surgery and medical therapy, and the risks of
ystematic bias inherent to observational studies, because the
nvestigators were more prone to publish studies with good
esults than studies in which mortality and complications rates
ere high. 3) The criteria for determining patient suitability for
EVAR versus open surgery were not explicitly declared in
any studies. 4) Most studies had limited samples (also
ecause of the limited prevalence of the disease). Despite the
equirement for studies to have included a minimum of 20 type
aortic dissections for each category, larger numbers would
ave provided more powerful data. 5) Even with extensive
fforts to systematically address the risk of including overlap-
ing patient populations in this analysis, we acknowledge that
here may be some remaining undetected duplication and
verlapping data that could not be identified.
Further higher-level studies on type B aortic dissection
tratified by type and timing, with long-term assessment of
utcomes are required to provide optimal treatment strategy
tionissecirectives on the disease.
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